The Myelin Repair Foundation (MRF) today announced it has entered a Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health (NIH) to assess MRF-008, as a potential therapeutic for multiple sclerosis (MS). This CRADA will facilitate collaboration between the MRF and National Institute of Neurological Disorders and Stroke (NINDS) at the NIH Clinical Center to study MRF-008, a drug identified by the MRF as a potential neuroprotective therapeutic to enhance repair in multiple sclerosis patients.
Through its Accelerated Research Collaboration™ (ARC™) model, a collaborative research model designed to accelerate promising therapeutics to market, the Myelin Repair Foundation will work closely with the NIH to assess MRF-008 as a therapeutic candidate in an MS clinical trial. MRF-008 is a generic FDA-approved compound for the treatment of hypertension identified by the Myelin Repair Foundation's academic research consortium as a novel drug repurposing candidate for neuroprotection to stimulate MS repair. Dr. Irene Cortese, M.D. and Dr. Daniel Reich, M.D., Ph.D. will lead the research study at the NIH.
